WO2005071105A1 - An essential hypertension associated gene and the detecting method and the usage thereof - Google Patents
An essential hypertension associated gene and the detecting method and the usage thereof Download PDFInfo
- Publication number
- WO2005071105A1 WO2005071105A1 PCT/CN2004/000021 CN2004000021W WO2005071105A1 WO 2005071105 A1 WO2005071105 A1 WO 2005071105A1 CN 2004000021 W CN2004000021 W CN 2004000021W WO 2005071105 A1 WO2005071105 A1 WO 2005071105A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adrenergic receptor
- essential hypertension
- detecting
- gene
- site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a disease-related gene, and particularly to a gene related to essential hypertension.
- the present invention also relates to a mutated ⁇ -1 adrenergic receptor gene, a detection method and use thereof.
- the invention also relates to a method for predicting the relative risk of essential hypertension in vitro and a kit for detecting an ⁇ -1A adrenergic receptor gene.
- the present invention finally relates to the application of the above-mentioned mutant gene, detection method, and method for predicting the relative risk of primary hypertension in vitro in the prevention, diagnosis, or treatment of primary hypertension. Background technique
- Hypertension is a common and frequently-occurring disease that endangers human health. Coronary heart disease and stroke caused by it have become the leading cause of human death. There is an urgent need for effective methods and drugs that can prevent, diagnose or treat primary hypertension. Although humans have invested a lot of human and material resources in the research of hypertension, the pathogenesis of hypertension has not been fully clarified so far. Previous epidemiological and clinical studies have shown that hypertension has a clear tendency to cluster in families, indicating that hypertension is closely related to genetic factors. From the perspective of molecular biology, some gene structural abnormalities and / or abnormal expressions are the root cause of hypertension. Among them, gene mutation, gene translocation and abnormal gene regulation play a considerable role. It is now thought that abnormal renin gene, angiotensin, angiotensin-converting enzyme gene and proto-oncogene may be related to the formation of high blood pressure.
- beta receptors There are two types of receptors that can bind to catecholamines (including norepinephrine, epinephrine, etc.).
- ⁇ -adrenergic receptor a-adrenergic receptor
- beta-adrenergic receptors beta-type adrenergic receptors or known as beta-type adrenergic receptors (referred to as beta receptors).
- the smooth muscle effects produced by the combination of catecholamines and alpha receptors are mainly excitatory, including vasoconstriction, uterine contraction, iris radial muscle contraction, etc .; but there are also inhibitory, such as small intestinal relaxation; some effectors only have alpha receptors, Some have only beta receptors, and some have both alpha and beta receptors.
- Alpha receptors are divided into 03 ⁇ 4 and (3 ⁇ 4) subtypes, which are determined according to the selective action of different receptor blockers.
- prazosin can selectively block the receptor
- yohimbine can selectively block the ⁇ 2 receptor
- phentolamine has a blocking effect on both the receptor and the receptor, but the effect on the receptor is more than
- the effect on the ⁇ 2 receptor is 3-5 times greater.
- the alpha receptors of the presynaptic membrane are different from the alpha receptors of the posterior membrane, the former being an alpha 2 type and the latter being a type.
- Alpha-1 adrenergic receptors are members of the G protein-coupled receptor superfamily, which activates mitosis and regulates growth and proliferation in a variety of cells.
- ⁇ -1-ARs Alpha-1 adrenergic receptors
- ⁇ -1A- adrenergic receptor ⁇ -1 ⁇ - adrenergic receptor; adrenergic, ⁇ -1 ⁇ , receptor, abbreviation: ADRA1A
- -1C 'adrenoceptor ct-lC- adrenergic receptor; adrenergic ic, ct- 1C-, receptor
- CX '-1 ⁇ adrenergic receptor 1 isoform ⁇ -1 ⁇ — adrenergic receptor i soform 1 ⁇ ' -1A adrenergic receptor 2 isoform ⁇ -1 ⁇ — adrenergic receptor isoform 2 ⁇ '-1A adrenal ⁇ -1A—adrenergic receptor isoform 3 ⁇ -1A adrenergic receptor isoform 3 -1A— adrenergic receptor isoform 4 -1A
- Four transcripts were produced. These four transcripts encode proteins with different C-termini, but have similar binding characteristics to the 'gland'. An overview of selective shearing and expression, and the distribution of polymorphic positions in Chinese samples are shown in Figure 1.
- the -1 ⁇ adrenergic receptor gene is currently identified on the human chromosome 8p22. At present, there are no mutations in the receptor gene, the relationship between the mutation in the receptor gene and essential hypertension, and the detection methods, kits, and their application prospects in forecasting and new drug development. Road. Summary of the invention
- an object of the present invention is to provide a mutated ⁇ -1A adrenergic receptor gene. Another object of the present invention is to provide a method for detecting the alpha-1A adrenergic receptor gene of the present invention.
- Another object of the present invention is to provide a method for predicting the risk of essential hypertension in an individual to be tested in vitro.
- Another object of the present invention is to provide a method for detecting a mutated ⁇ -1A adrenergic receptor gene in the prevention, diagnosis or treatment of essential hypertension.
- Another object of the present invention is to provide the application of a method for detecting essential hypertension genes in the prevention, diagnosis or treatment of essential hypertension.
- Another object of the present invention is to provide an in vitro method for detecting the presence of a primary hypertensive blood pressure-related gene in a test sample in the prevention, diagnosis or treatment of primary hypertension.
- Another object of the present invention is to provide an in vitro method for predicting the risk of essential hypertension in a test subject in the prevention, diagnosis or treatment of essential hypertension.
- Another object of the present invention is to provide an application of a kit for detecting ⁇ -1A adrenal pixel receptor gene in the prevention, diagnosis or treatment of essential hypertension.
- the present invention provides a mutated oc -1 ⁇ adrenergic receptor gene, the nucleoside of the gene!
- the naming principle of the C 2 547 / G polymorphic site is: In the sequence of the five exons of the ADRA1A gene shown in FIG. 1, C 2547 / G is at position 2547. In the entire genomic sequence including the intron, if the first nucleotide of the first exon is at position +1, the polymorphism is located at position +99522.
- This polymorphism is located at position 1735 in the mRNA sequence of the ⁇ -1A adrenergic receptor type 4 isoform. ⁇ Use five exons hypothetical ligation sequences instead of naming the mRNA sequence to prevent confusion with the relative positions of polymorphisms in other mRNA isoforms. Position in the gene: This polymorphism is located in the 3 'untranslated region (UTR) of the a-1A adrenergic receptor mRNA type 4 isoform.
- the polymorphic 5, flanking region (5, flanking region) is: "AACATTTTAGGAA", which can help find the C2547 / G locus.
- the so-called "gene polymorphism” refers to the differences in the nucleotide sequences of individual genes in a population.
- the polymorphic site in the present invention is a single nucleotide polymorphism (SNP) site, that is, a single nucleotide in a genomic sequence is changed; the difference in nucleotide sequence can Reflected at the DNA level or the RNA level, the ⁇ -1 A adrenergic receptor gene polymorphism of the present invention can be reflected at the DNA 7 level, the RNA? Level, preferably the leg A level, and more preferably the genomic DNA.
- SNP single nucleotide polymorphism
- the ADRA1A gene is confirmed to be a related gene of essential hypertension.
- the human chromosome region 8p22 in which ADRA1A is located and the human protozoa are obtained in 148 Han hypertension families.
- Example 2 Scientific evidence for the linkage between essential hypertension and blood pressure levels, see Example 2; By comparing the frequency distribution of the C2547 / G polymorphism in 503 cases and 504 controls, the C2547 / G polymorphic G allele is derived The distribution of genes in the cases was significantly higher than in the control group (see Example 3); the relative risk of primary hypertension in C2547 / G polymorphic G allele carriers was significantly increased in 1007 subjects (see also Example 4); C2547 / G polymorphic G allele carriers had significantly higher systolic and diastolic blood pressure levels than C / C genotype carriers (see Example 5).
- the present invention provides a method for detecting the mutant ⁇ -1A adrenergic receptor gene of the present invention.
- Methods known to those skilled in the art can be used to detect the mutated cc-1A adrenaline receptor gene of the present invention.
- direct sequencing of DNA can directly reveal sequence differences between a control gene and a gene carrying the mutation. The sensitivity of this method is greatly improved when used in combination with polymerase reaction (PCR). Act (Sanger et al., PNAS, 1977, 74: 5463-5467).
- the nucleotide sequence may also be determined using a commercial sequencing kit or an automatic sequencer.
- the conventional automated sequencing method uses radioactive or fluorescent labels to determine the nuclear ⁇ column.
- Restriction fragment polymorphism analysis can also be used to detect polymorphic sites of the CC-1A adrenergic receptor gene sequence in vivo.
- the method for detecting a polymorphic site of the ct-1A adrenergic receptor gene sequence in vitro is a combination of a polymerization reaction and a direct sequencing method.
- RNA level corresponding to DNA The difference in the nucleotide sequence of the present invention is also reflected in the RNA level corresponding to DNA. Detection of RNA levels usually includes the following steps: (1) Extraction and purification of RM.
- RM Extraction and purification of RM.
- the RNA is separated from other cell components, such as DNA, proteins, and cell debris, by treating with an organic solvent such as phenol and chloroform and centrifuging. To avoid non-specific degradation, RNA purification should be performed as quickly as possible under denaturing conditions.
- RNA end labeling To carry out the radioactive phosphate labeling of the 5 and 5 ends of RNA, there must be a 5, -hydroxyl, the cap structure must be removed with tobacco acid pyrophosphate and phosphatase, and the 5 and 5 end phosphorylated RNA must be alkaline ' ⁇ phosphoesterase Dephosphorize and inactivate this enzyme. 5.
- Dephosphorylated RNA can be phosphorylated with T4 polynucleoside S kinase (PNK) with high specific activity.
- PNK polynucleoside S kinase
- PNK can transfer [ ⁇ - 32 P]-ATP [ ⁇ - 32 P]-phosphate to RNA 5, -End. Labeling the 3, -terminus of RNA [5, -32 P]-pCp is generally linked to the 3, -terminus of RNA using T4 RNA ligase. (3) RNA sequence determination. The use of RNase and S1-protected nuclease protection assays or chemical cleavage methods can detect sequence changes at specific locations, such as Cotton et al., PNAS, USA, 85: 4397- 4401 (1985)) 0 In addition, using a commercial sequencing kit can be measured directly RNA sequence. In the present invention, detection of position 1735 in the mRNA sequence of the type 4 isomer corresponding to the ⁇ -1A adrenergic receptor gene C2547 / G site is preferred.
- the invention provides a method for detecting genes related to essential hypertension by the body. After a large number of experimental studies, the present invention proves that the ⁇ -1 A adrenergic receptor gene of the present invention is a related gene of essential hypertension with conclusive solid face evidence.
- the specific evidence is as follows: In 148 Chinese families of hypertension The scientific evidence of the linkage between the human chromosomal region 8p22 in which ADRA1A is located and human essential hypertension and blood pressure levels is obtained, see Example 2; by comparing the C2547 / G polymorphism in 503 cases and 504 controls The frequency distribution shows that the distribution of C2547 / G polymorphic G alleles in cases is significantly higher than that of the control group (see Example 3); C2547 / G polymorphic G allele carriers occur in 1007 subjects The relative risk of essential hypertension was significantly increased (see Example 4); C2547 / G polymorphic G allele carriers had significantly higher systolic and diastolic blood pressure levels than those of C / C genotype carriers (see Implementation Example 5).
- the present invention provides a method for detecting genes related to essential hypertension in vitro, which method comprises detecting a polymorphism of an ⁇ -1A adrenergic receptor gene C2547 / G site.
- any method for detecting the polymorphism at the C2547 / G site of the ⁇ -1A adrenergic receptor gene may be adopted, and preferably a combination of a polymerase chain reaction and a direct sequencing method.
- the invention also provides a method for in vitro detection of the presence of genes related to essential hypertension in a test sample, the method comprising:
- Samples containing the genes of the invention can be obtained from cells from a subject, such as cells from blood, urine, saliva, gastric juice, hair, biopsies and autopsy materials. Especially from blood.
- the conventional method known in the art can be used to extract the ⁇ -1A adrenergic receptor gene of the present invention.
- C2547 / G site polymorphism can be detected by any method known to those skilled in the art for detecting ⁇ -1A adrenergic receptor gene C2547 / G site polymorphism, preferably polymerase chain reaction Combined with direct sequencing.
- a person in the blood of an individual to be tested is first extracted, and an oc-lA adrenergic receptor gene fragment containing a C2547 / G polymorphic site is amplified by PCR, and the PCR is performed by direct sequencing. The amplified fragment was analyzed to determine whether the ⁇ -1A adrenergic receptor C2547 / G site was G.
- the present invention further provides an in vitro method for the prediction of risk of essential hypertension test subject, the method comprising detecting in vitro a sample from an individual to be tested ⁇ _1 A adrenoceptor polymorphism C2547 / G sites,
- the risk of primary hypertension in individuals carrying the G allele was significantly higher than that of individuals carrying the C allele.
- the test individual is a Chinese Han nationality.
- the method for detecting the polymorphism of the ⁇ -1A adrenergic receptor gene C2547 / G site can adopt any known detection method, preferably a combination of a polymerase chain reaction and a direct sequencing method.
- the present invention proves that from the different aspects of the ADRA1A gene C2547 / G site, individuals carrying the G allele are at greater risk of developing essential hypertension than individuals carrying the C allele.
- the risk of hypertension is significantly increased.
- 148 Chinese families with hypertension have obtained scientific evidence that there is a linkage between the human chromosome region 8 ⁇ 22 in which ADRA1A is located and human essential hypertension and blood pressure levels.
- Example 2 The frequency distribution of the C2547 / G polymorphic G allele in the cases and 504 controls was significantly higher than that in the control group (see Example 3); C2547 / G polymorphism in 1007 subjects G allele carriers have a significantly increased relative risk of developing essential hypertension (see Example 4); C2547 / G polymorphic G allele carriers have significantly higher systolic and diastolic blood pressure levels than C / C genotype carrier (Example 5).
- the method of the present invention can be used alone, that is, detecting the polymorphism of the C2547 / G polymorphism in the sample from the individual to be tested, in order to predict in vitro that the individual is highly primary Blood pressure risk.
- those skilled in the art know that the occurrence of essential hypertension and the result of multiple factors work together, so the present invention can also be achieved with other methods known in the art, such as Tacpan technology, SnaPshot technology, etc. Purpose of predicting the risk of hypertension in test subjects in vitro.
- the present invention provides a kit for in vitro detection of the ⁇ -1A adrenergic receptor gene.
- the kit may contain one or more containers, and the container is provided for detecting One or more components of the ADRA1A gene at a genetic locus. Depending on the specific detection method and polymorphism detection site, the kit may contain different components. At the same time, it can provide information about the manufacture, use, and sale of drugs or biological products that has been reviewed by government drug regulatory agencies.
- a kit for detecting an ⁇ -1A adrenergic receptor gene in vitro is provided. The kit includes:
- the primers for amplifying polymorphic sites can be designed according to the known nucleotide sequences of the present invention, usually 15 to 30 bases, and the GC content is about 45% to 50%. It can specifically bind to the template at the appropriate temperature, which can be designed using a special computer program, such as (Oligo 6.53 software). As shown in Example 1 of the present invention, this is a primer for amplifying the C-1547 / G site of the ex-1A adrenergic receptor gene:
- the PCR amplified enzyme can be Tag DNA polymerization Enzymes, lenow fragments, Tth DNA polymerase, VENT DNA polymerase and other enzymes can be used for PCR amplification.
- the reagents used to detect the C2547 / G site in the test j box vary according to the detection method.
- the present invention provides a kit for detecting ⁇ -1A adrenergic receptor gene using PCR and direct sequencing.
- the kit contains:
- Reagent for detecting C2547 / G site polymorphism for example, ddNTP labeled with four fluorescent dyes, sequencing enzyme, dNTP.
- the kit for detecting a cc-1A adrenergic receptor gene of a C2547 / G polymorphism can be used to detect a polymorphism of hypertension-related genes in vitro.
- the invention provides an application of a mutated C-1A adrenergic receptor gene in the prevention, diagnosis or treatment of essential hypertension. Since the present invention shows that the mutant gene of the present invention is closely related to the occurrence and development of essential hypertension, the present invention can be used for the prevention, diagnosis or treatment of essential hypertension.
- the present invention provides an application of a method for detecting a mutated ⁇ -1A adrenergic receptor gene in the prevention, diagnosis or treatment of essential hypertension.
- the invention provides an application of a method for detecting genes related to essential hypertension in the prevention, diagnosis or treatment of essential hypertension.
- the invention provides an in vitro method for detecting the presence of a gene related to essential hypertension in a sample to be tested, and the method is used for the prevention, diagnosis or treatment of essential hypertension.
- the invention provides an application of a method for predicting the risk of primary hypertension in a test individual in vitro in the prevention, diagnosis or treatment of primary hypertension.
- the invention provides an application of a kit for detecting the -1A adrenergic receptor gene in the prevention, diagnosis or treatment of essential hypertension.
- Figure 1 shows the selective splicing of the ADRA1A gene. ⁇ Polymorphic position distribution in Chinese samples.
- Figure 2 is a sequencing map of the ADRA1A gene C2547 / G polymorphic locus. Among them, Figure 2A shows the G / G genotype; Figure 2B shows the G / C genotype; and Figure 2C shows the C / C genotype. detailed description
- a C2547 / G polymorphic amplified fragment (618 bp) was obtained using polymerase chain reaction (PCR). For each plate, 2 samples were added with the DNA template of the test sample, the control reaction, and the blank control reaction without the A sample. C2547 / G polymorphic primers and amplifications are shown in Tables 2 and 3.
- Sequencing is performed on multiple models of DNA sequencing instruments using the recommended setting. Each plate was sequenced with 2 samples of DNA samples to be tested, a control sample, and a blank control sample without DNA samples.
- the 3700 sequencer (PE company in the United States) can be used to easily and quickly read sequencing results.
- flanking region (5, flanking region) "GCAAATA" can help find and read the C2547 / G polymorphic genotype.
- the reverse sequencing result of the C2547 / G polymorphic site in Figure 2A is C, so the forward sequencing result at this site should be the G allele, and the The genotype should be the G / G genotype;
- the C2547 / G polymorphic site in Figure 2B is bimodal, so the genotype of the test individual containing the gene should be the G / C genotype;
- C2547 / G polymorphism in Figure 2C The result of the reverse sequencing of the genetic locus is G, so the forward sequencing result of the locus should be the C allele, and the genotype of the test individual containing the gene should be the C / C genotype.
- Example 2 ADRAIA ⁇ chromosome region 8p22 and human essential hypertension; scientific evidence of a linkage between pressure levels
- Example 1 The method in Example 1 was used to analyze the C2547 / G polymorphism in 1007 cases and controls, and further statistical analysis (using SAS software package, multiple logistic regression analysis), the results are shown in Table 8.
- Example 1 The method in Example 1 was used to analyze the C2547 / G polymorphism in 525 men, and further statistical analysis (using SAS software package, multiple logist ic regression analysis), the results are shown in Table 9.
- Table 9 Relative risk variable OR (% 95 CI) of C2547 / G polymorphisms to essential hypertension in 525 men P
- BMI body mass index
- triglycerides triglycerides
- blood creatinine triglycerides
- blood glucose values were adjusted using covariance analysis (SAS software package, ANC0VA analysis).
- BMI body mass index
- Covariance analysis was used to adjust BMI, triglycerides, blood creatinine, and blood glucose levels.
- Kit for in vitro detection of alpha -1 alpha adrenergic receptor gene contains:
- PCR amplification enzymes and corresponding buffers Tag DNA polymerase, 10X buffer, dNTP;
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2004800398386A CN1902327B (zh) | 2004-01-07 | 2004-01-07 | 一种原发性高血压相关基因及其检测方法和用途 |
PCT/CN2004/000021 WO2005071105A1 (en) | 2004-01-07 | 2004-01-07 | An essential hypertension associated gene and the detecting method and the usage thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2004/000021 WO2005071105A1 (en) | 2004-01-07 | 2004-01-07 | An essential hypertension associated gene and the detecting method and the usage thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005071105A1 true WO2005071105A1 (en) | 2005-08-04 |
Family
ID=34800353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2004/000021 WO2005071105A1 (en) | 2004-01-07 | 2004-01-07 | An essential hypertension associated gene and the detecting method and the usage thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1902327B (zh) |
WO (1) | WO2005071105A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101979657B (zh) * | 2010-05-11 | 2013-02-27 | 首都医科大学附属北京安贞医院 | 高血压易感基因的rs2878677位点的检测试剂盒 |
CN101886129B (zh) * | 2010-06-30 | 2012-11-21 | 首都医科大学附属北京安贞医院 | 高血压易感基因AGTR1单核苷酸多态性位点rs388915的检测方法及检测试剂盒 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079561A2 (en) * | 2000-04-17 | 2001-10-25 | Liggett Stephen B | Alpha-2 adrenergic receptor polymorphisms |
WO2001088126A2 (en) * | 2000-05-15 | 2001-11-22 | Bayer Aktiengesellschaft | REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR |
-
2004
- 2004-01-07 WO PCT/CN2004/000021 patent/WO2005071105A1/zh active Application Filing
- 2004-01-07 CN CN2004800398386A patent/CN1902327B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079561A2 (en) * | 2000-04-17 | 2001-10-25 | Liggett Stephen B | Alpha-2 adrenergic receptor polymorphisms |
WO2001088126A2 (en) * | 2000-05-15 | 2001-11-22 | Bayer Aktiengesellschaft | REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR |
Non-Patent Citations (3)
Title |
---|
CHANG D.J. ET AL: "Molecular cloning, genomic characterization and expression of novel human alpha A-Adrenoceptor isoforms", FEBS LETT., vol. 422, no. 2, January 1998 (1998-01-01), pages 279 - 283, XP004261822 * |
XU W. ET AL: "The relationship between angiotensin II type 1 receptor gene A1166C polymorphism and essential hypertension", J. CLIN. CARDIOL., vol. 18, no. 11, November 2002 (2002-11-01) * |
ZHU J.: "Association analysis of beta2 adrenergic receptor polymorphisms with hypertension in Chiese", JOURNAL OF MEDICAL POSTGRADUATES, vol. 16, no. 2, February 2003 (2003-02-01) * |
Also Published As
Publication number | Publication date |
---|---|
CN1902327A (zh) | 2007-01-24 |
CN1902327B (zh) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200291478A1 (en) | Identification of polymorphic sequences in mixtures of genomic dna | |
TWI541507B (zh) | 評估肝臟病變之方法 | |
WO2014181107A9 (en) | Genetic method of aiding the diagnosis and treatment of familial hypercholesterolaemia | |
AU2016286088A1 (en) | Single nucleotide polymorphism in HLA-B*15:02 and use thereof | |
JP4140329B2 (ja) | 高血圧のリスク診断方法 | |
CN104894230A (zh) | 一种hla-dqb1基因分型的组特异性引物pcr-sbt方法及试剂 | |
MXPA06012744A (es) | Marcadores de haplotipo y metodos para utilizarlos en la determinacion de la respuesta al tratamiento. | |
WO2005071105A1 (en) | An essential hypertension associated gene and the detecting method and the usage thereof | |
TWI351436B (en) | Method for detecting a risk of the development of | |
Middleton | HLA typing from serology to sequencing era | |
Purkait et al. | Renin-angiotensin-aldosterone system gene polymorphisms in Type 2 diabetic patients among the Mewari population of Rajasthan | |
US8236497B2 (en) | Methods of diagnosing cardiovascular disease | |
KR101617612B1 (ko) | 한국인의 고혈압 예측용 snp 마커 | |
KR102511596B1 (ko) | 단일염기다형성을 이용한 안지오텐신 전환효소억제제 이상반응 진단용 조성물 및 이를 이용한 방법 | |
JP2007514417A (ja) | アルツハイマー病の進行に関連するntrk1遺伝子マーカー | |
WO2015037681A1 (ja) | 抗甲状腺薬誘発性無顆粒球症リスクを判定するための検査方法及び判定用キット | |
KR101213173B1 (ko) | 유방암과 연관된 단일염기다형성 및 그의 용도 | |
JP4444576B2 (ja) | 2型糖尿病関連遺伝子 | |
JP4998874B2 (ja) | 炎症性疾患の判定方法 | |
JP4502570B2 (ja) | 遺伝子多型解析を用いたIgA腎症診断およびIgA腎症診断用キット | |
JP4825956B2 (ja) | 気道粘膜炎症性疾患の罹患リスクの判定 | |
KR20230150127A (ko) | 심근경색과 연관된 유전자 다형성 및 그의 용도 | |
KR20150092937A (ko) | 한국인의 고혈압 예측용 snp 마커 | |
EP2823054B1 (en) | Genetic factors in blood pressure | |
JP2004512842A (ja) | インスリン遺伝子の5’隣接領域におけるアリル変異および体脂肪に基づく、インスリン非依存型糖尿病のリスク評価方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480039838.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase |